The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

A randomized controlled trial to compare the safety and efficacy of sirolimus-eluting biodegradable polymer ultra-thin stent (SUPRAFLEX Cruz) and everolimus-eluting biodegradable polymer stent (SYNERGY) in treatment for three-vessel coronary artery disease: design of the Multivessel TALENT trial

DOI: 10.4244/EIJ-D-20-00772

1. Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands 
2. Department of cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland 
3. Department of Cardiology, Radbound University, Nijmegen, The Netherlands
4. Health Research Board Clinical Research Facility, Department of Medicine, NUIG, Galway, Ireland
5. Department of Cardiology, St. Johannes Hospital, Dortmund, Germany
6. Division of Image Processing, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
7. Department of Cardiology, Clinic Hospital, Barcelona, Spain
8. Department of Cardiology, Freeman Hospital and Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK
9. Lambe Institute for Translational Research, School of Medicine, NUIG, Galway, Ireland
10.NHLI, Imperial College London, London, UK 

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention and external reviewers - has been published immediately upon acceptance as it was received in the last round of revision. The content of this article is the responsibility of the authors.

Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.

To read the full content of this article, please log in to download the PDF.

Aims: The purpose of the Multivessel TALENT trial is to compare clinical outcomes of novel SUPRAFLEX Cruz stent with those of SYNERGY stent in patients with three vessel disease (3VD) undergoing state-of-the-art percutaneous coronary intervention (PCI).

Methods and results: In this prospective, randomized, 1:1 balanced, multi-center, open-label trial, 1550 patients with de novo 3VD without left main disease are assigned to the SUPRAFLEX Cruz or SYNERGY arm. The following treatment principles of the “best practice” PCI will be applied: Heart Team consensus based on SYNTAX Score II treatment recommendation, functional lesion evaluation by quantitative flow ratio (QFR), stent optimization by intravascular imaging, optimal pharmacological treatment and prasugrel monotherapy. The primary endpoint is a non-inferiority comparison of patient-oriented composite endpoint (POCE) of all-cause death, any stroke, any myocardial infarction, or any revascularization, at 12 months post-procedure. The powered secondary endpoint is a superiority comparison of vessel-oriented composite endpoint (VOCE) defined as vessel-related cardiovascular death, vessel-related myocardial infarction, or clinically and physiologically-indicated-target vessel revascularization, at 24 months.

Conclusions: The Multivessel TALENT trial will be evaluating a novel treatment strategy for complex coronary artery disease with state-of-the-art PCI based on angiography-derived QFR with novel ultra-thin SUPRAFLEX Cruz stents, compared with the SYNERGY stents.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Culprit lesion location and outcomes in patients with multi-vessel disease and infarct-related cardiogenic shock. A core laboratory analysis of the CULPRIT-SHOCK trial